AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...
Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...
Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding light on the company’s chances of competing for a market targeted by rivals ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...
Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...
Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...
| GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, ...
The FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent ...
Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results